MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

Clinical trials for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS explained in plain language.

Never miss a new study

Get alerted when new MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS trials appear

Sign up with your email to follow new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 6 Not yet recruiting 2 Not yet finished but already full! 1

New hope for transplant patients battling recurring liver disease

Disease control Ongoing

This study is testing whether an oral medication called resmetirom can reduce harmful fat buildup in the liver of people who have had a liver transplant. It will involve 120 participants who have developed fatty liver disease after their transplant. The main goal is to see if the…

Matched conditions: MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS

Get alerted when new MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS trials appear

New hope for transplant patients battling recurring liver disease